Trump's visit to the UK brings the US another $30 billion from the pharmaceutical giant

British biopharmaceutical company GSK has announced a $30 billion investment in the United States over five years amid a visit by the US President Donald Trump to the country. About writes Reuters.

The company's investments will be used to develop research and development, clinical trials, and supply chain improvements.

Half of GSK's revenues last year came from the United States, so the new facilities should combine research and production in the United States and the United Kingdom and strengthen the positions of both countries in the biotechnology sector.

One of the main projects will be the construction of a new $1.2 billion plant in Pennsylvania to produce new drugs for respiratory diseases and cancer. Work will begin in 2026.

In addition, the company is investing in artificial intelligence, digital technologies, production of new medicinal substances, and improvement of medical device assembly at five facilities in the United States.

These investments are expected to create tens of thousands of new jobs, and the US will be the first country to be ranked by the number of clinical trials, participants and sites conducted by GSK over the next five years.

U.S. Secretary of Commerce Howard Luthnick emphasized that the project will allow the development and production of critical medicines right in the United States.

Prime Minister of the United Kingdom Keir Starmer called the investment "a powerful example of U.S.-U.K. cooperation that improves health, creates opportunity, and spurs economic growth."

GSK also clarified that over the past year, it has already invested about $2 billion in production in the United States.

• Trump and his wife Melanie arrived late in the evening of September 16 in the UK – This is his second state visit as president, which is being called historic.
• During the visit, the United States and Britain are expected to sign agreements in three areas for more than $10 billion.